Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

To discover, develop, and commercialize transformative therapies to cure blindness caused by a range of genetic, orphan, and degenerative retinal disorders.

To be the leader in discovering and developing transformative therapies to save and restore vision in people with debilitating retinal diseases.

Ocugen has received a number of awards and recognition, including the 2016 Hitachi Foundation’s Social Innovation Award, the 2014 Indian Council of Medical Research’s Award for Excellence in Basic and Translational Research, and the 2015 Prix Galien Switzerland Award.